{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:32:50Z","timestamp":1772051570585,"version":"3.50.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1097\/bor.0b013e3283025ec2","type":"journal-article","created":{"date-parts":[[2008,6,2]],"date-time":"2008-06-02T07:05:29Z","timestamp":1212390329000},"page":"443-449","source":"Crossref","is-referenced-by-count":64,"title":["Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies"],"prefix":"10.1097","volume":"20","author":[{"given":"Joseph","family":"Keane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Bresnihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R4-13-20210128","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"key":"R5-13-20210128","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/art.21705","article-title":"Glucocorticoid use, other associated factors, and the risk of tuberculosis","volume":"55","author":"Jick","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.bor.0000127594.92432.7c","article-title":"Infectious complications of treatment with biologic agents","volume":"16","author":"Hamilton","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/IAI.01011-07","article-title":"Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs","volume":"76","author":"Chakravarty","year":"2008","journal-title":"Infect Immun"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis","volume":"43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2005.10.004","article-title":"The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TNFalpha therapy","volume":"72","author":"Tubach","year":"2005","journal-title":"Joint Bone Spine"},{"key":"R14-13-20210128","first-page":"247","article-title":"Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience","volume":"31","author":"Fonseca","year":"2006","journal-title":"Acta Reumatol Port"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1513\/pats.200508-091JS","article-title":"Immunosuppression related to collagen-vascular disease or its treatment","volume":"2","author":"Hamilton","year":"2005","journal-title":"Proc Am Thorac Soc"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"699","DOI":"10.7326\/0003-4819-147-10-200711200-00006","article-title":"Brief communication: characteristics of spontaneous cases of tuberculosis associated with infliximab","volume":"147","author":"Raval","year":"2007","journal-title":"Ann Intern Med"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor {alpha}-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"R19-13-20210128","first-page":"221S","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection [comment].","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-{alpha} treatment.","volume":"60","year":"2005","journal-title":"Thorax"},{"key":"R21-13-20210128","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003.","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R24-13-20210128","first-page":"6","article-title":"Tumour necrosis factor-a and tuberculosis: guidance from the National TB Advisory Committee Irish Med","volume":"101","author":"Kavanagh","year":"2008","journal-title":"J"},{"key":"R25-13-20210128","first-page":"620","article-title":"Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy","volume":"137","author":"Beglinger","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJM200107193450307","article-title":"Management of tuberculosis in the United States","volume":"345","author":"Small","year":"2001","journal-title":"N Engl J Med"},{"key":"R27-13-20210128","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMcp021045","article-title":"Latent tuberculosis infection","volume":"347","author":"Jasmer","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1542-3565(04)00060-6","article-title":"High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy","volume":"2","author":"Mow","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R29-13-20210128","first-page":"263","article-title":"Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis","volume":"42","author":"Coaccioli","year":"2000","journal-title":"Panminerva Med"},{"key":"R30-13-20210128","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R31-13-20210128","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.200607-907ED","article-title":"Weighing gold or counting spots: which is more sensitive to diagnose latent tuberculosis infection?","volume":"174","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"R32-13-20210128","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"R33-13-20210128","first-page":"49","article-title":"Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"R34-13-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.200701-024ED","article-title":"The new IGRA and the old TST: making good use of disagreement","volume":"175","author":"Pai","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R35-13-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1164\/rccm.200608-1099OC","article-title":"Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts","volume":"175","author":"Arend","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R36-13-20210128","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/00002030-200211220-00008","article-title":"Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells","volume":"16","author":"Chapman","year":"2002","journal-title":"AIDS"},{"key":"R37-13-20210128","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2215\/CJN.01280406","article-title":"Detecting latent tuberculosis infection in hemodialysis patients: a head-to-head comparison of the T-SPOT.TB test, tuberculin skin test, and an expert physician panel","volume":"2","author":"Passalent","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R38-13-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1183\/09031936.06.00110205","article-title":"Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients","volume":"28","author":"Piana","year":"2006","journal-title":"Eur Respir J"},{"key":"R39-13-20210128","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon {gamma} assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R40-13-20210128","first-page":"474","article-title":"Infliximab does not suppress the tuberculin skin test (purified protein derivative)","volume":"34","author":"Hatemi","year":"2007","journal-title":"J Rheumatol"},{"key":"R41-13-20210128","first-page":"555","article-title":"Efficacy of various duration of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"R42-13-20210128","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 3","key":"R43-13-20210128","first-page":"265","article-title":"Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe","volume":"64","author":"Perez","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"R44-13-20210128","doi-asserted-by":"crossref","first-page":"858a","DOI":"10.1164\/ajrccm.175.8.858a","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"175","author":"Saukkonen","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"R45-13-20210128","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"key":"R46-13-20210128","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis","volume":"10","author":"Sichletidis","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"R47-13-20210128","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1183\/09031936.00034007","article-title":"Patient choice promotes adherence in preventive treatment for latent tuberculosis","volume":"30","author":"Rennie","year":"2007","journal-title":"Eur Respir J"},{"key":"R48-13-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.2007.072967","article-title":"Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis","volume":"67","author":"Takeuchi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R49-13-20210128","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1086\/522993","article-title":"A patient with de novo tuberculosis during anti-tumor necrosis factor therapy illustrating diagnostic pitfalls and paradoxical response to treatment","volume":"45","author":"Arend","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R50-13-20210128","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa055524","article-title":"Microscopic-observation drug-susceptibility assay for the diagnosis of TB","volume":"355","author":"Moore","year":"2006","journal-title":"N Engl J Med"},{"key":"R51-13-20210128","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1148\/radiographics.21.4.g01jl06839","article-title":"Thoracic sequelae and complications of tuberculosis","volume":"21","author":"Kim","year":"2001","journal-title":"Radiographics"},{"key":"R52-13-20210128","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1001\/archinte.1993.00410040062009","article-title":"Mycobacterium tuberculosis bacteremia in patients with and without human immunodeficiency virus infection","volume":"153","author":"Bouza","year":"1993","journal-title":"Arch Intern Med"},{"key":"R53-13-20210128","first-page":"1376","article-title":"Am J Respir Crit Care M","volume":"161","year":"2000","journal-title":"ed"},{"key":"R54-13-20210128","first-page":"1057","article-title":"Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab","volume":"9","author":"Belknap","year":"2005","journal-title":"Int J Tuberc Lung Dis"},{"key":"R55-13-20210128","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMc053468","article-title":"Infliximab for rheumatoid arthritis in a patient with tuberculosis","volume":"355","author":"Matsumoto","year":"2006","journal-title":"N Engl J Med"},{"key":"R56-13-20210128","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/art.23210","article-title":"Is it safe to readminister tumor necrosis factor? Antagonists following tuberculosis flare?","volume":"58","author":"Aslanidis","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R57-13-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"R58-13-20210128","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised antiinterferon {gamma} antibody, in patients with moderate to severe Crohn's disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"R59-13-20210128","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R60-13-20210128","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"R61-13-20210128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e3283025ec2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:57:02Z","timestamp":1620946622000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200807000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e3283025ec2","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}